SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's stellar earnings and robust AI-driven guidance were surprisingly met with a sharp sell-off, prompting intense community discussion centered on potential institutional options manipulation and overvaluation fears within the broader AI sector, with many investors actively calling it a strategic dip-buying opportunity.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a reported financial turnaround and an improved outlook, driven by new Material Transfer Agreements, particularly in oncology, and securing a non-dilutive credit facility. The community is actively discussing the company's strategic pivot to its Matrix-M adjuvant platform and the potential for a significant short squeeze.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending after a substantial earnings and guidance miss triggered a sharp sell-off, igniting a fierce debate among investors. Many view the dip as an overreaction and a strategic buying opportunity for its energy storage technology, while a vocal segment criticizes management's credibility and forecasts further downside.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is highly active ahead of its earnings report and recent management commentary at the CAGNY conference, with community sentiment sharply divided over CEO performance and widespread speculation regarding a potential Pepsi buyout, even as impressive sales growth from Celsius and Alani Nu continues to draw bullish long-term conviction.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is rallying sharply following a strong earnings beat, robust revenue growth, and key announcements including a major quantum-secure network deployment in Europe and a significant defense contract. The community is actively debating if current momentum, fueled by short-squeeze potential and strategic wins, can overcome persistent valuation concerns in the evolving quantum computing sector.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending with high anticipation ahead of its earnings report, as its expanding agentic AI platform through new offerings like Sales Assist and a strategic India innovation hub fuels investor excitement, while a notable short interest adds to community speculation about its valuation and growing presence across diverse sectors.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following its Q4 2025 earnings report, which surpassed revenue and EPS expectations. This has ignited a community debate, with bulls citing the company's strong free cash flow and deep undervaluation, while bears remain focused on long-term growth challenges and management's execution.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing significant community attention ahead of its earnings, with optimism stemming from its vital role in AI infrastructure through custom ASICs and networking, along with projections for doubling AI revenue and substantial chip sales by 2027. This bullish outlook contrasts with some investors' anxieties over broader market movements and potential margin impacts.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending following its mixed Q4 earnings report and the announcement of CEO Doug Ingram's upcoming retirement, fueling community debate around the stock's perceived undervaluation. Investors are actively discussing potential catalysts like upcoming pipeline data from its siRNA programs and renewed buyout speculation, amidst persistent claims of market manipulation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as a significant earnings beat and robust revenue growth are met with investor frustration over the stock's stagnant price action, igniting community debate and speculation about a potential buyout or partnership amidst management's notable silence regarding its AUR200 pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead

Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a catalyst-rich 2026 at Oppenheimer's 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and...

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group

Jefferies Financial Group raised Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven research firms that are currently covering the firm...

Corbus Pharmaceuticals (NASDAQ:CRBP) COO Ian Hodgson Sells 2,415 Shares

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) COO Ian Hodgson sold 2,415 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven analysts that are currently covering the company...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the stock...

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss.</li><li>The study showed that participants reported reductions in food-related thoughts and cravings</li><li>Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026.</li></ul>Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) surged 36% in premarket trading on Thursday after the company announced encouraging Phase 1a results for CRB-913, an oral CB1 inverse agonist targeting chronic obesity.At the time of writing, <a href="https://stocktwits.com/symbol/CRBP">CRBP</a> was among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Results Of The Study</h2>Corbus Pharma said that the single-and multiple-ascending dose study showed that CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events reported. Gastrointestinal issues were minimal, and daily neuropsychiatric assessments remained negative, indicating no signs of suicidality, depression, or anxiety.Participants reported reductions in food-related thoughts and cravings, highlighting early behavioral effects alongside weight reduction. Pharmacokinetic analysis confirmed that CRB-913 is suitable for once-daily oral dosing.Building on the early results, Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026. This next stage will further explore optimal dosing and continue evaluating safety, tolerability, and efficacy over a longer period.CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. Unlike earlier drugs in this class that raised neuropsychiatric safety concerns, CRB-913 is designed for limited brain penetration to reduce those risks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘extremely’ bullish from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.One user expressed optimism about the CANYON-1 study.<stembedurl>https://stocktwits.com/LuigiDurante/message/638840548</stembedurl>Year-to-date, the stock has declined nearly 15%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-appears-set-to-retest-200-dma-last-time-it-did-its-rebound-didn-t-endure/cLIxBZBREnI">MSFT Stock Appears Set To Retest 200-DMA – Last Time It Did, Its Rebound Didn’t Endure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?

Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.

Equity

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...

B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBP
Corbus Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News

CRBPCorbus Pharmaceuticals Holdings Inc